Pacira ( PCRX ) Q2 Revenue Rises 1.7%
Pacira BioSciences ( NASDAQ:PCRX ) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% ( ...
PRSA-NY Big Apple Awards Winners Shortlist Announced and Tickets Now Available for the 2025 Gala
NEW YORK, July 25, 2025 ( GLOBE NEWSWIRE ) -- PRSA-NY has officially unveiled today the shortlist for the 2025 Big Apple Awards, celebrating excellence in public relations across the New York area.
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 - Pacira BioSciences ( NASDAQ:PCRX )
BRISBANE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. PCRX, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close ...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., July 03, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new ...
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 - Pacira BioSciences ( NASDAQ:PCRX )
- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah's Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc.
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. ( NYSE: DV ) ; NAPCO Securities Technologies, Inc. ( NASDAQ: NSSC ) ; Pacira Biosciences, Inc. ( NASDAQ: PCRX ) ; and Treace Medical Concepts, Inc. ( NASDAQ: TMCI ) - NAPCO Security Techs ( NASDAQ:NSSC ) , DoubleVerify Holdings ( NYSE:DV )
PHILADELPHIA, May 26, 2025 ( GLOBE NEWSWIRE ) -- If you have held DoubleVerify Holdings, Inc.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
Data will be featured at the ASGCT 28th Annual Meeting Data will be featured at the ASGCT 28th Annual Meeting ...
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - Pacira BioSciences ( NASDAQ:PCRX )
BRISBANE, Calif., May 02, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc.
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Beam Therapeutics ( NASDAQ:BEAM ) , B2Gold ( AMEX:BTG )
U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's session. Baird analyst Jonathan Komp upgraded the rating for Wolverine World Wide from Neutral to Outperform.
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan ...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., April 11, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira's Amended and ...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule ...
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps - Pacira BioSciences ( NASDAQ:PCRX )
Exparel Q4 2024 net sales hit $147.7 million, up 3% year over year. Fresenius gets generic license for limited sales starting early 2030. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday - Apple ( NASDAQ:AAPL ) , Applied Optoelectronics ( NASDAQ:AAOI )
U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday. Shares of Marvell Technology, Inc. MRVL rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet Business for $2.5 billion in cash.
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations ...
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL - Pacira BioSciences ( NASDAQ:PCRX )
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations ...
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual - Pacira BioSciences ( NASDAQ:PCRX )
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc.
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that ...
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences - Pacira BioSciences ( NASDAQ:PCRX )
Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%.
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, March 13, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. PCRX between August 2, 2023 and August 8, 2024, both dates inclusive ( the "Class Period" ) , of the important March 14, 2025 ...
Pacira BioSciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 14, 2025 Deadline to file Lead Plaintiff Motion - Pacira BioSciences ( NASDAQ:PCRX )
Investors can contact the law firm at no cost to learn more about recovering their losses
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, March 13, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ( "Pacira" or the "Company" ) PCRX of a class action securities lawsuit.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Pacira BioSciences ( NASDAQ:PCRX )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Pacira To Contact Him Directly To Discuss Their Options
PCRX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, March 06, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. PCRX between August 2, 2023 and August 8, 2024, both dates inclusive ( the "Class Period" ) , of the important March 14, 2025 ...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
PARSIPPANY, N.J., March 06, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira's Amended and ...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Pacira BioSciences ( NASDAQ:PCRX )
PARSIPPANY, N.J., March 06, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc.
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Pacira BioSciences and Golden Entertainment in the Box have been highlighted as Zacks Bull and Bear of the Day
Chicago, IL - March 5, 2025 - Zacks Equity Research shares Pacira BioSciences ( PCRX Quick QuotePCRX - ) as the Bull of the Day and Golden Entertainment ( GDEN Quick QuoteGDEN - ) as the Bear of the Day.
Bull of the Day: Pacira BioSciences ( PCRX )
Earnings moving in the right direction and a bounce off technical support sets this stop up nicely.
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW ORLEANS, March 04, 2025 ( GLOBE NEWSWIRE ) -- Kahn Swick & Foti, LLC ( "KSF" ) and KSF partner, former Attorney General of Louisiana, Charles C.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Ensign Group Expands Healthcare Portfolio With Key Acquisitions
ENSG acquires skilled nursing and senior living facilities across four states, expanding its U.S. footprint and bringing higher revenues for its Skilled Services segment.
Shareholders that lost money on Pacira BioSciences, Inc. ( PCRX ) should contact Levi & Korsinsky about pending Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, March 04, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ( "Pacira" or the "Company" ) PCRX of a class action securities lawsuit.
PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. PCRX between August 2, 2023 and August 8, 2024, both dates inclusive ( the "Class Period" ) , of the important March 14, 2025 ...
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Pacira BioSciences ( NASDAQ:PCRX )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
PCRX DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action - PCRX - Pacira BioSciences ( NASDAQ:PCRX )
NEW YORK, Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. PCRX between August 2, 2023 and August 8, 2024, both dates inclusive ( the "Class Period" ) , of the important March 14, 2025 lead ...
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
